9820
Global X China Biotech ETF
Solactive China Biotech NR CNH
NAV as of
4 Week: 8.14 - 8.85
52 Week: 6.87 - 10.40
Latest Closing Price
8.36
Premium / Discount
0
Expense Ratio
0.68%
Investment Objective
The ETF seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -2.85 | 1.77 | -1.61 |
| 1 Day | -0.89 | 0.00 | 0.00 |
| 1 Week | -0.36 | 4.50 | -0.08 |
| 1 Month | -2.45 | 7.22 | -0.34 |
| 3 Months | 2.39 | 13.89 | 0.17 |
| 6 Months | 18.67 | 24.55 | 0.76 |
| 1 Year | -21.65 | 34.70 | -0.62 |
| 2 Years | -42.02 | 50.20 | -0.84 |
| 3 Years | 0.00 | 0.00 | 0.00 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 69.6975 | -19.6517 | -26.0911 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 3.0000 | 82.0000 | 85.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| N.A | ||
Portfolio Data
Total Number of Holdings: 31
Number of Bond Holdings: 0
Number of Equity Holdings: 30
Total Market Value: 737,120,144
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 11.0727 | 1,912,796 | -22,500 | 81,619,005 |
| 2 | Wuxi AppTec Co Ltd Class A | 8.9965 | 826,051 | -9,600 | 66,315,374 |
| 3 | Walvax Biotechnology Co Ltd Class A | 8.9463 | 1,801,285 | -21,300 | 65,945,044 |
| 4 | WuXi Biologics (Cayman) Inc | 7.2128 | 1,207,590 | -13,500 | 53,167,093 |
| 5 | Innovent Biologics Inc | 7.0218 | 1,528,300 | -18,000 | 51,759,333 |
| 6 | Sino Biopharmaceutical Ltd | 6.4083 | 12,306,672 | -144,000 | 47,236,569 |
| 7 | Shanghai RAAS Blood Products Co Ltd Class A | 4.7480 | 5,590,794 | -65,700 | 34,998,370 |
| 8 | Hualan Biological Engineering Inc Class A | 3.8394 | 1,262,293 | -15,000 | 28,300,609 |
| 9 | Akeso Inc Ordinary Shares | 2.8317 | 570,268 | -6,000 | 20,873,344 |
| 10 | Hygeia Healthcare Holdings Co Ltd Ordinary Shares | 2.7740 | 399,767 | -4,800 | 20,447,381 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 27.28 |
| Large | 54.26 |
| Medium | 13.19 |
| Small | 5.23 |
| Micro | 0.00 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
15.9170
Price/Book*
3.3571
Price/Sales*
4.7094
Price/Cash Flow*
16.6740
Dividend Yield*
1.6447
Growth Measures
Long-Term Earnings
18.6253
Historical Earnings
37.3303
Sales Growth
18.2083
Cash-Flow Growth
12.1204
Book-Value Growth
10.4845
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
